Evidence map›Paper›PMID 33939590›Full record

ArticleJournal of biomolecular structure & dynamics2022

Vaishali Chandel, Garima Tripathi, Seema A Nayar, Brijesh Rathi, Abhijeet Kumar, Dhruv Kumar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomolecular structure & dynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vaishali ChandelAmity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Noida 201313, India.
Garima TripathiDepartment of Chemistry, T. N. B. College, TMBU, Bhgalpur, Bihar, India.
Seema A NayarDepartment of Microbiology, Government Medical College, Trivandrum, India.
Brijesh RathiLaboratory for Translational Chemistry and Drug Discovery, Department of Chemistry, Hansraj College, University of Delhi, New Delhi, India.
Abhijeet KumarDepartment of Chemistry, Mahatma Gandhi Central University Motihari 845401, India.
Dhruv KumarAmity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Noida 201313, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused COVID-19 has emerged as a severe threat to the life of human kind. The identification and designing of appropriate and reliable drug molecule for the treatment of COVID-19 patients is the pressing need of the present time. Among different drug targets, the main protease of SARS-CoV-2 is being considered as most effective target. In addition to the drug repurposing, different compounds of natural as well as synthetic origins are being investigated for their efficacy against different drug targets of SARS-CoV-2 virus. In that context, the chromone based natural flavonols have also exhibited significant antiviral properties against different targets of SARS-CoV-2. The

Indexed as

COVID-19SARS-CoV-2Drug RepositioningHumansMolecular Docking SimulationMolecular Dynamics SimulationPeptide HydrolasesProtease InhibitorsPeptide HydrolasesProtease InhibitorsADMEArylchromoneCOVID-19main proteasemolecular dockingmolecular dynamics simulation

Identifiers

PMID33939590
PMCPMC8108196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.